Study Sites. CRO will use best efforts to assure that all study sites perform the Study in accordance with the Agreement.
Study Sites. The DMFs are currently installed in six government-run district hospitals across six regions in Ghana (Figure 4): Bole District Hospital in the Northern Region, Kintampo District Hospital in the Xxxxxx-Ahafo Region, Mampong-Asante District Hospital in the Xxxxxxx Region, Kete-Kratchi Government Hospital in the Volta Region, Apam Catholic Hospital the Central Region, and Axim Hospital in the Western Region. These district-level hospitals serve both urban and rural populations of between 100,000 and 200,000 people and use a centralized water distribution systems provided by their respective municipalities.
Study Sites. The data used in this analysis represents a part of a larger research study analyzing fecal associated pathogen contamination of produce farms in northeast Mexico near the U.S. border (Nueva Xxxx, Coahuila, and Tamaulipas) between 2011 and 2012 (34, 56). This agricultural area of Mexico was selected due to large quantities of produce types of interest, ideal sampling plans, and a primary selling market in the United States. The produce of interest in this study included tomatoes (Solanum lycopersicum), jalapeños (Capsicum annuum), and cantaloupes (Cucumis melo var. cantalupensis). For each produce type, the Mexican state produce associations and the state Secretariat for Agriculture selected 3 to 5 farms to be sampled. A total of 11 farms were included in this study. Seven farms exclusively grew one type of produce; this included one jalapeño farm, one tomato farm, and five cantaloupe farms. Four farms grew both jalapeños peppers and tomatoes. This protocol for sampling was reviewed and approved by three Institutional Review Boards (IRB) located at La Universidad Autónoma de Nuevo Xxxx (UANL), North Carolina State University (NCSU), and Emory University (Emory IRB: 00035460, Appendix A).
Study Sites. The reference benthic communities belong to two EASIZ Programme key-sites, for which a background knowledge already exists and from which important study material is available:
Study Sites. The study will take place at: UR Medicine Breast Imaging 000 Xxx Xxxxx Xxxxx Xxxxxxxxx, XX 00000 The subject enrollment and scan will take place at UR Medicine Breast Imaging.
Study Sites. EUSwitzerland – 1 site German – 6 sites total Ireland – 3 sites United Kingdom – 5 sites Belgium – 1 site France – 5 sites The Netherlands – 2 sites FDA Agreements Post-Marketing Study (Sky0101-010) • Objectives of Post-Marketing Study • Fulfill FDA post-marketing requirement (all patients) • NDA expedited review of surrogate endpoint pivotal LM study based on CSF clearance of malignant cells • Patient population: lymphomatous meningitis and solid tumor • Primary endpoint neurological progression free survival • Expand label (STNM Subgroup of patients) • Current NDA indication lymphomatous meningitis • Add solid tumor neoplastic meningitis • Expand study to include European study sites • Improve enrollment • Pooling of US and European data acceptable • Differences in patient management acknowledged by FDA • One significant pivotal study sufficient for STNM approval • P<.0366 for each of two independent primary efficacy analysis • Enroll patients until 72 events occur in STNM subgroup • Event driven analysis • Interim sample size adjustment net necessary • 67% of patient enrolled are STNM • >90% of patients will have an event prior to 2-yr. follow-up • Approximately 110 additional patients will be enrolled • Enrollment complete 2H’04 • As of 18 December 2002 • 42 Patients Randomized • 12 lymphoma patients • 30 solid tumor patients • Regulatory Filings • US • Pre-supplemental NDA meeting 1Q2005 • NDA 2Q2005 • Europe • Pre-MAA Meeting 1Q2005 • Scientific Advice 1Q2005 • MAA (EU) 2Q2005
Study Sites. The study was conducted in communities surrounding DSI’s Gadyen Dlo’s Léogâne, Jolivert and the North Parish programs (see Figure 3). Figure 3 DSI Program Sites and Household Coverage in Communities Served Figure from (Xxxxxx, 2012b)
Study Sites. The 40 ha pilot-scale facility is situated along a portion of the back end of the 2190 ha Central flow path of STA-3/4. The upstream vegetation communities include emergent macrophytes (primarily Typha domingensis) while SAV becomes more dominant in the downstream half of the flow way. The limerock substrate PSTA cell therefore comprises a final back end treatment process for a portion of the flow in the central flow path (Figure 1). Operations of the PSTA cell were initiated in 2007, and by January 2012 an average of 9.2 cm (3.5-19 cm, N = 39) of marl had accumulated above the limerock substrate (Xxxxxxx et al. 2013).
Study Sites. We measured present and historical soil bed level dynamics in different estuarine habitats across five European estuaries from three different regions, distributed along a latitudinal range: the Mondego estuary, in Coimbra (Portugal); the Santoña Marshes estuary, the Xxxxx (Bay of Santander) and Oyambre estuary in Cantabria (Spain); and the Western Scheldt in Zeeland (The Netherlands) (Figure 1). All estuaries except Oyambre are fed by relatively large rivers. On the contrary, Oyambre is mainly fed by surficial runoff and the input of small creeks, among which Río Turbio that flows into the east branch, is the largest. In order to reflect differences in sedimentation patterns associated to variability in the river and tidal flow, we considered different estuarine sections, from inner areas to areas closed to the estuary mouth. We considered both vegetated habitats and tidal flats, inhabited by macro benthos, which have received much less attention than vegetated communities (e.g. saltmarshes) despite being critical ecosystems in the estuary (e.g. providing food for migratory species). We analysed the relationship of sedimentary vs. erosional trends with natural (e.g. wind) and anthropogenic factors (e.g. xxxxx) in order to understand the long-term tendency of the estuarine communities and their potential for carbon sequestration and coastal protection in the long-term.
Study Sites. Each study site and investigator proposed by Ascent for participation in the study must be approved by Unicycive prior to initiation of any on-site study-related activities involving that study site or investigator. Following receipt of such approval by Unicycive, Ascent will assist with negotiation and execution of a clinical trial agreement with each such investigator in the form approved by Unicycive. Unless otherwise specifically requested by Unicycive in writing or required under Applicable Law, Ascent will not contract directly as a party to any clinical trial agreements with participating study sites. The clinical trial agreements and any modifications thereto shall be subject to the written approval of Unicycive prior to any use thereof.
